|
|
|
|
|
|
by sam537
1353 days ago
|
|
|
This is the bottleneck for one company. We have many companies this size doing the same thing. The issue is large companies (novartis/BMS) sometimes sit on compounds and refuse to develop because they think it may not be worth it, may think a certain disease (read market) is saturated, or they may be waiting for the 'right time'. It can be frustrating. Smaller companies have 2-3 compounds which they actively work to develop but most of them end up getting acquired by the big fish. |
|
|